Reactive oxygen species modulator-1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients

Hong Jun Kim, Min Jee Jo, Bo Ram Kim, Jung Lim Kim, Yoon A. Jeong, Yoo Jin Na, Seong Hye Park, Suk Young Lee, Dae Hee Lee, Hye Seung Lee, Baek-Hui Kim, Sun Il Lee, Byung Wook Min, Young Do Yoo, Sang Cheul Oh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Reactive oxygen species modulator-1 (Romo1) is a novel protein that has been reported to be crucial for cancer cell proliferation and invasion. However, its clinical implications in colorectal cancer patients are not well-known. For the first time, we investigated the association between Romo1 and the clinical outcomes of colorectal cancer patients. Study We examined Romo1 expression in resected tumor tissues immunohistochemically and assessed it with histological scores. We conducted survival analyses for patients who had curative resection (n = 190) in accordance with clinical parameters including level of Romo1 expression, and we examined the association between Romo1 expression and cell invasion using Matrigel invasion assay in colorectal cancer cells. Results We observed significantly longer mean disease-free survival in the low Romo1 group compared with the high Romo1 group (161 vs 127.6 months, p = 0.035), and the median overall survival of the low Romo1 group was significantly longer than that of the high Romo1 group (196.9 vs 171.3 months, p = 0.036). Cell invasiveness decreased in the Romo1 knockdown colorectal cancer cells in contrast to the controlled cells. Romo1 overexpression in tumor tissue was associated with a high lymph node ratio between the metastatic and examined lymph nodes (p = 0.025). Conclusions Romo1 overexpression in tumor tissue was significantly associated with survival in curatively resected colorectal cancer patients, suggesting Romo1 expression as a potential adverse prognostic marker. Increased Romo1 expression was found to be associated with high lymph node ratio. Cancer invasiveness appeared to be a key reason for the poor survival related to highly expressed Romo1.

Original languageEnglish
Article numbere0176834
JournalPLoS One
Volume12
Issue number5
DOIs
Publication statusPublished - 2017 May 1

Fingerprint

colorectal neoplasms
Modulators
prognosis
reactive oxygen species
Colorectal Neoplasms
Reactive Oxygen Species
lymph nodes
Tumors
neoplasms
cell invasion
Lymph Nodes
Neoplasms
Tissue
Survival
Cells
Association reactions
Cell proliferation
resection
Survival Analysis
Disease-Free Survival

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Reactive oxygen species modulator-1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients. / Kim, Hong Jun; Jo, Min Jee; Kim, Bo Ram; Kim, Jung Lim; Jeong, Yoon A.; Na, Yoo Jin; Park, Seong Hye; Lee, Suk Young; Lee, Dae Hee; Lee, Hye Seung; Kim, Baek-Hui; Lee, Sun Il; Min, Byung Wook; Yoo, Young Do; Oh, Sang Cheul.

In: PLoS One, Vol. 12, No. 5, e0176834, 01.05.2017.

Research output: Contribution to journalArticle

Kim, Hong Jun ; Jo, Min Jee ; Kim, Bo Ram ; Kim, Jung Lim ; Jeong, Yoon A. ; Na, Yoo Jin ; Park, Seong Hye ; Lee, Suk Young ; Lee, Dae Hee ; Lee, Hye Seung ; Kim, Baek-Hui ; Lee, Sun Il ; Min, Byung Wook ; Yoo, Young Do ; Oh, Sang Cheul. / Reactive oxygen species modulator-1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients. In: PLoS One. 2017 ; Vol. 12, No. 5.
@article{3287369de5704a81875b4f5a49e32d42,
title = "Reactive oxygen species modulator-1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients",
abstract = "Background Reactive oxygen species modulator-1 (Romo1) is a novel protein that has been reported to be crucial for cancer cell proliferation and invasion. However, its clinical implications in colorectal cancer patients are not well-known. For the first time, we investigated the association between Romo1 and the clinical outcomes of colorectal cancer patients. Study We examined Romo1 expression in resected tumor tissues immunohistochemically and assessed it with histological scores. We conducted survival analyses for patients who had curative resection (n = 190) in accordance with clinical parameters including level of Romo1 expression, and we examined the association between Romo1 expression and cell invasion using Matrigel invasion assay in colorectal cancer cells. Results We observed significantly longer mean disease-free survival in the low Romo1 group compared with the high Romo1 group (161 vs 127.6 months, p = 0.035), and the median overall survival of the low Romo1 group was significantly longer than that of the high Romo1 group (196.9 vs 171.3 months, p = 0.036). Cell invasiveness decreased in the Romo1 knockdown colorectal cancer cells in contrast to the controlled cells. Romo1 overexpression in tumor tissue was associated with a high lymph node ratio between the metastatic and examined lymph nodes (p = 0.025). Conclusions Romo1 overexpression in tumor tissue was significantly associated with survival in curatively resected colorectal cancer patients, suggesting Romo1 expression as a potential adverse prognostic marker. Increased Romo1 expression was found to be associated with high lymph node ratio. Cancer invasiveness appeared to be a key reason for the poor survival related to highly expressed Romo1.",
author = "Kim, {Hong Jun} and Jo, {Min Jee} and Kim, {Bo Ram} and Kim, {Jung Lim} and Jeong, {Yoon A.} and Na, {Yoo Jin} and Park, {Seong Hye} and Lee, {Suk Young} and Lee, {Dae Hee} and Lee, {Hye Seung} and Baek-Hui Kim and Lee, {Sun Il} and Min, {Byung Wook} and Yoo, {Young Do} and Oh, {Sang Cheul}",
year = "2017",
month = "5",
day = "1",
doi = "10.1371/journal.pone.0176834",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Reactive oxygen species modulator-1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients

AU - Kim, Hong Jun

AU - Jo, Min Jee

AU - Kim, Bo Ram

AU - Kim, Jung Lim

AU - Jeong, Yoon A.

AU - Na, Yoo Jin

AU - Park, Seong Hye

AU - Lee, Suk Young

AU - Lee, Dae Hee

AU - Lee, Hye Seung

AU - Kim, Baek-Hui

AU - Lee, Sun Il

AU - Min, Byung Wook

AU - Yoo, Young Do

AU - Oh, Sang Cheul

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background Reactive oxygen species modulator-1 (Romo1) is a novel protein that has been reported to be crucial for cancer cell proliferation and invasion. However, its clinical implications in colorectal cancer patients are not well-known. For the first time, we investigated the association between Romo1 and the clinical outcomes of colorectal cancer patients. Study We examined Romo1 expression in resected tumor tissues immunohistochemically and assessed it with histological scores. We conducted survival analyses for patients who had curative resection (n = 190) in accordance with clinical parameters including level of Romo1 expression, and we examined the association between Romo1 expression and cell invasion using Matrigel invasion assay in colorectal cancer cells. Results We observed significantly longer mean disease-free survival in the low Romo1 group compared with the high Romo1 group (161 vs 127.6 months, p = 0.035), and the median overall survival of the low Romo1 group was significantly longer than that of the high Romo1 group (196.9 vs 171.3 months, p = 0.036). Cell invasiveness decreased in the Romo1 knockdown colorectal cancer cells in contrast to the controlled cells. Romo1 overexpression in tumor tissue was associated with a high lymph node ratio between the metastatic and examined lymph nodes (p = 0.025). Conclusions Romo1 overexpression in tumor tissue was significantly associated with survival in curatively resected colorectal cancer patients, suggesting Romo1 expression as a potential adverse prognostic marker. Increased Romo1 expression was found to be associated with high lymph node ratio. Cancer invasiveness appeared to be a key reason for the poor survival related to highly expressed Romo1.

AB - Background Reactive oxygen species modulator-1 (Romo1) is a novel protein that has been reported to be crucial for cancer cell proliferation and invasion. However, its clinical implications in colorectal cancer patients are not well-known. For the first time, we investigated the association between Romo1 and the clinical outcomes of colorectal cancer patients. Study We examined Romo1 expression in resected tumor tissues immunohistochemically and assessed it with histological scores. We conducted survival analyses for patients who had curative resection (n = 190) in accordance with clinical parameters including level of Romo1 expression, and we examined the association between Romo1 expression and cell invasion using Matrigel invasion assay in colorectal cancer cells. Results We observed significantly longer mean disease-free survival in the low Romo1 group compared with the high Romo1 group (161 vs 127.6 months, p = 0.035), and the median overall survival of the low Romo1 group was significantly longer than that of the high Romo1 group (196.9 vs 171.3 months, p = 0.036). Cell invasiveness decreased in the Romo1 knockdown colorectal cancer cells in contrast to the controlled cells. Romo1 overexpression in tumor tissue was associated with a high lymph node ratio between the metastatic and examined lymph nodes (p = 0.025). Conclusions Romo1 overexpression in tumor tissue was significantly associated with survival in curatively resected colorectal cancer patients, suggesting Romo1 expression as a potential adverse prognostic marker. Increased Romo1 expression was found to be associated with high lymph node ratio. Cancer invasiveness appeared to be a key reason for the poor survival related to highly expressed Romo1.

UR - http://www.scopus.com/inward/record.url?scp=85019143296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019143296&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0176834

DO - 10.1371/journal.pone.0176834

M3 - Article

C2 - 28472059

AN - SCOPUS:85019143296

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e0176834

ER -